This study is in progress, not accepting new patients
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Orange, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- EMD Serono Research & Development Institute, Inc.
- Links
- Trial Awareness and Transparency website US Medical Information website, Medical Resources
- ID
- NCT03631706
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 304 people participating
- Last Updated